Abstract 3158
Background
Continued smoking after a HNC diagnosis is associated with poorer outcomes. Proximity to tobacco retail outlets is negatively associated with cessation in non-cancer patients (pts) but this has not been evaluated in cancer survivors. We evaluated the impact of tobacco retail access on cessation in HNC pts.
Methods
HNC pts (Princess Margaret Cancer Centre, Toronto, Canada) completed questionnaires at diagnosis and follow up (median 26 months apart) evaluating changes in tobacco use. Validated tobacco retail location data were obtained from Ontario Ministry of Health and pt home addresses were geocoded using ArcGIS 10.6.1, which calculated walking time/distance to nearest vendor and vendor density within 250 meters (m) and 500m from pts. Multivariable logistic regression and Cox proportional hazard models evaluated the impact of vendor availability on cessation and time to quitting after diagnosis respectively, adjusted for significant clinico-demographic and tobacco covariates.
Results
141/450 HNC pts smoked at diagnosis; quit rate after diagnosis was 48%. Mean distance and walking time to a vendor was 1.2 km (range 0-10) and 14 min (range 0-116). On average, there was 1 vendor (range 0-19) within 250m and 3 vendors (range 0-19) within 500m from pts; 33% and 56% of pts lived within 250m and 500m from at least one vendor, respectively. Greater distance (aOR 1.27 per 1000m [95% CI 1.01-1.59] p = 0.04) and increased walking time (aOR 1.02 per min [1.00-1.04] p = 0.04) to a vendor were associated with a higher quit rate at one year. Living near more vendors within 500m was associated with an increasing dose effect on reducing cessation rates at 1 year (aOR 0.90 per vendor [0.82-0.99] p = 0.03). Greater distance (aHR 1.18 per 1000m [1.01-1.38] p = 0.04) and increased walking time (aHR 1.01 per min [1.00-1.03] p = 0.04) to a vendor were also associated with quitting at any time. Living near more vendors within 500m had a trend towards reducing quit rates at any time (aHR 0.94 per vendor [0.88-1.00] p = 0.07).
Conclusions
Close proximity to tobacco retail outlets is associated with reduced cessation rates for HNC survivors. Reducing density of tobacco vendors is a cessation strategy that can positively impact HNC pt outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract